Sg Americas Securities, LLC Allovir, Inc. Transaction History

Sg Americas Securities, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$0.64 - $0.78 $181 - $220	283 Added 1.64%	17,584 $13,000
Q4 2023 Jan 12, 2024	SELL	$0.68 - $2.39 $4,074 - $14,320	-5,992 Reduced 25.72%	17,301 $12,000
Q3 2023 Oct 13, 2023	BUY	$2.15 - $3.64 $50,079 - $84,786	23,293 New	23,293 $50,000
Q1 2023 Apr 28, 2023	BUY	$3.94 - $7.05 $15,129 - $27,072	3,840 Added 30.85%	16,288 $64,000
Q4 2022 Feb 02, 2023	BUY	$4.7 - $9.98 $164 - $349	35 Added 0.28%	12,448 $64,000
Q3 2022 Oct 31, 2022	SELL	$4.13 - $8.79 $1,106 - $2,355	-268 Reduced 2.11%	12,413 $98,000
Q2 2022 Jul 29, 2022	BUY	$3.26 - $7.06 $41,340 - $89,527	12,681 New	12,681 $49,000
Q4 2021 Feb 07, 2022	SELL	$12.94 - $25.99 $197,347 - $396,373	-15,251 Closed	0 $0
Q3 2021 Nov 01, 2021	BUY	$16.97 - $25.06 $66,132 - $97,658	3,897 Added 34.32%	15,251 $382,000
Q2 2021 Aug 12, 2021	BUY	$19.44 - $25.06 $21,286 - $27,440	1,095 Added 10.67%	11,354 $224,000
Q1 2021 May 13, 2021	BUY	$20.81 - $45.5 $213,489 - $466,784	10,259 New	10,259 $240,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.